Incyte's Enterprise Value for the quarter that ended in Dec. 2023 was $10,465 Mil.
Incyte's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $837 Mil. Incyte's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2023 was 7.99%.
The historical rank and industry rank for Incyte's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
INCY'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2.02 Med: 0.6 Max: 10.04
Current: 10.05
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Incyte was 10.04%. The lowest was -2.02%. And the median was 0.60%.
INCY's Earnings Yield (Joel Greenblatt) % is ranked better than 95.95% of 1406
companies
in the Biotechnology industry
Industry Median: -15.095
vs INCY: 10.05
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Incyte's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2023 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Incyte Earnings Yield (Joel Greenblatt) % Historical Data
The historical data trend for Incyte's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Incyte Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Earnings Yield (Joel Greenblatt) %
2.91
-1.33
4.11
3.62
7.99
Incyte Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Earnings Yield (Joel Greenblatt) %
3.62
3.93
5.33
6.83
7.99
Competitive Comparison
For the Biotechnology subindustry, Incyte's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Incyte Earnings Yield (Joel Greenblatt) % Distribution
For the Biotechnology industry and Healthcare sector, Incyte's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Incyte's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Incytes Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as
Incyte's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $837 Mil.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Incyte Earnings Yield (Joel Greenblatt) % Related Terms
Thank you for viewing the detailed overview of Incyte's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INCY has been successfully added to your 